SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Padcev

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market. First FDA approval was December 2019; latest label expansion July 2026.
Why 4/10
Padcev is already FDA-approved and commercially launched with no pending regulatory decision; the last PDUFA (August 17, 2026) was resolved with early approval on July 10, 2026. The next potential catalyst is the EV-309 Phase 3 bladder-sparing readout, but it is still recruiting with no fixed date. As an approved drug at a diversified mega-cap pharma, impactScore is 4.
Actionable Insight NEUTRAL

Watch for EV-309 (bladder-sparing) Phase 3 data readout, listed on Pfizer's 2026 pipeline catalyst page but still recruiting per ESMO 2026. Any positive readout could support another label expansion. Near-term, track quarterly sales growth trajectory as the July 2026 MIBC label expansion ramps.

Price Chart

Loading chart...

Executive Summary

Padcev (enfortumab vedotin) is an FDA-approved antibody-drug conjugate targeting Nectin-4 for bladder cancer, co-developed by Astellas and Pfizer (Pfizer acquired Seagen in 2023). Originally approved in 2019, it received a major label expansion on July 10, 2026 for perioperative treatment of muscle-invasive bladder cancer regardless of cisplatin eligibility, and the European Commission expanded approval on October 23, 2026. Q3 2026 sales reached $720 million (23% YoY growth, beating consensus), helping drive Pfizer to raise full-year guidance. As an already-approved, commercially growing drug at a diversified mega-cap pharma with no imminent binary catalyst, the investment outlook is neutral.

How It Works

Padcev is an antibody-drug conjugate (ADC) that works like a guided missile. One part is an antibody that latches onto Nectin-4, a protein found on the surface of bladder cancer cells. Once attached, the drug releases a chemotherapy payload (MMAE) directly inside the cancer cell, disrupting its internal skeleton and killing it. This targeted approach aims to spare healthy cells.

Trial Status

Padcev is FDA-approved in multiple bladder cancer settings. The Phase 3 EV-302 trial (1L metastatic urothelial cancer) and EV-303/EV-304 trials (perioperative MIBC) have all reported positive results supporting approvals. The Phase 3 EV-309 trial (bladder-sparing approach) is currently recruiting.

The Two-Sided Case

▲ Bull Case5
Padcev Q3 2026 revenue hit $720 million, beating the $658M consensus and growing 23% year-over-year, driven by market share gains and the new July 2026 MIBC perioperative label expansion.
The July 2026 FDA approval for Padcev + Keytruda in muscle-invasive bladder cancer regardless of cisplatin eligibility opens a large new patient population and is the first platinum-free perioperative regimen.
European Commission expanded approval on October 23, 2026 for resectable MIBC, adding international growth runway.
Pfizer raised full-year 2026 guidance citing strong Padcev and Eliquis demand, and launched/acquired products grew 32% operationally in Q3.
The EV-309 Phase 3 trial testing Padcev + Keytruda for bladder preservation (avoiding cystectomy) could open another major indication if positive.
▼ Bear Case4
Pfizer's analyst consensus is mixed: only 13 of 34 analysts rate it Buy/Strong Buy, with a mean price target of $29.26 (2.5% below the current ~$30 stock price), implying limited upside.
Padcev faces competition from other ADCs and checkpoint inhibitor combinations in bladder cancer, including the VOLGA trial testing AstraZeneca's Imfinzi with Padcev as a rival regimen.
As a single product within Pfizer's $62-64B revenue base, Padcev's $720M quarterly contribution is meaningful but not company-transforming; Pfizer's stock is driven by many factors beyond this one drug.
Several large institutional holders trimmed or exited PFE in Q2 2026, including Wellington Management (trim 44%), Marshall Wace (near-exit 95%), and Point72 (full exit).

Upcoming Catalysts

  • EV-309 Phase 3 data readout for bladder-sparing treatment in MIBC (no fixed date; still recruiting per ESMO 2026)
  • Continued commercial ramp from July 2026 MIBC label expansion
  • Potential additional label expansions in earlier-stage bladder cancer settings

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 10

Hover a chip for the title
1 cnbc.com2 reuters.com3 newsroom.astellas.com4 newsroom.astellas.com5 newsroom.astellas.com6 zacks.com7 biospace.com8 pfizer.com9 pdufa.bio10 padcevhcp.com